Cell ther­a­py biotech nabs Se­ries A; Metagenome start­up snags $77M round

A can­cer cell ther­a­py biotech has reeled in about $20 mil­lion to push for­ward its on­go­ing Phase I.

Al­lo­plex Bio­ther­a­peu­tics has se­cured about $20 mil­lion of an es­ti­mat­ed $25 mil­lion round, per SEC pa­per­work. CEO Frank Bor­riel­lo post­ed to LinkedIn two months ago not­ing the com­pa­ny would look to close a Se­ries A by Jan. 27. Bor­riel­lo, a for­mer VP at Bax­al­ta, formed the US-Aus­tralian biotech in 2016.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.